"For over 20 years, Columbus Oncology and Hematology Associates have helped patients with cancer and blood disorders receive compassionate, individualized care. As a top-rated center for oncology in Dublin, OH, our physicians use evidence-based guidelines and treatment plans with every visit to our cancer treatment center. We are a certified member of the MD Anderson Cancer Network and feature a staff of world-class physicians. Ultimately, our goal is to help you feel confident in your treatment plan, our medical professionals, and the latest research and technology we have to offer. Give us a call or visit our website to learn more!"

During the past decade, Columbus Oncology and Hematology Associates Inc conducted 105 clinical trials. In the 10-year time frame, 105 clinical trials started and 74 clinical trials were completed, i.e. on average, 70.5% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 51 clinical trials were completed. i.e. 204% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Columbus Oncology and Hematology Associates Inc" #1 sponsor was "National Cancer Institute (NCI)" with 86 trials, followed by "SWOG Cancer Research Network" with 40 trials sponsored, "Alliance for Clinical Trials in Oncology" with 20 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 12 trials sponsored and "GOG Foundation" with 12 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Columbus Oncology and Hematology Associates Inc" #1 collaborator was "National Cancer Institute (NCI)" with 96 trials as a collaborator, "NRG Oncology" with 21 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Columbus Oncology and Hematology Associates Inc" are "Recurrent Ovarian Carcinoma" (11 trials), "Recurrent Squamous Cell Lung Carcinoma" (10 trials), "Stage IV Lung Cancer AJCC v8" (9 trials), "Recurrent Fallopian Tube Carcinoma" (8 trials) and "Recurrent Primary Peritoneal Carcinoma" (8 trials). Many other conditions were trialed in "Columbus Oncology and Hematology Associates Inc" in a lesser frequency.

Most popular intervention types in "Columbus Oncology and Hematology Associates Inc" are "Drug" (137 trials), "Other" (121 trials), "Biological" (76 trials), "Procedure" (43 trials) and "Radiation" (13 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (59 trials), "Quality-of-Life Assessment" (55 trials), "Questionnaire Administration" (29 trials), "Computed Tomography" (27 trials) and "Biospecimen Collection" (25 trials). Other intervention names were less common.

The vast majority of trials in "Columbus Oncology and Hematology Associates Inc" are 139 trials for "All" genders, 43 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Columbus Oncology and Hematology Associates Inc". undefined are not yet recruiting, 43 are recruiting, 94 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 37 completed trials in Columbus Oncology and Hematology Associates Inc, 3 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Columbus Oncology and Hematology Associates Inc, 6 "Phase 1" clinical trials were conducted, 87 "Phase 2" clinical trials and 89 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".